The company has not filed an annual or quarterly report since its Q1 FY2022 10-Q, filed May 13, 2022. Its latest SEC filing is a 25-NSE from Jul 19, 2022.
10-Q for Q1 FY2022, filed May 13, 2022
The sections below describe the company as of the FY2021 annual report.
Develops transdermal microneedle drug-delivery products, including a zolmitriptan patch for migraine patients and delivery programs for pharmaceutical partners.
10-K for FY2021, filed Mar 17, 2022Zosano Pharma Corporation is a clinical-stage biopharmaceutical company focused on providing rapid systemic administration of therapeutics…View ↗
Our development efforts are currently focused on our product candidate, M207, our proprietary formulation of zolmitriptan delivered…View ↗
Pursue additional product candidates We have conducted initial feasibility studies on a number of compounds which suggest that our System…View ↗
Pharmaceutical customers pay for feasibility research and development studies to test delivery of their drugs; revenue from the work is tied to progress, while exclusivity is spread over its term.
10-K for FY2021, filed Mar 17, 2022Currently, the Company's revenue is related to feasibility studies in which the Company provides research and development services to…View ↗
$785K
10-K for FY2021, filed Mar 18, 2022
$785K ↗
Pharmaceutical companies hire Zosano under signed contracts for feasibility studies testing whether its system can deliver their drugs.
10-K for FY2021, filed Mar 17, 2022Currently, the Company's revenue is related to feasibility studies in which the Company provides research and development services to…View ↗
No. It lost $29.9M in FY2021.
10-K for FY2021, filed Mar 18, 2022
−$31.5MView ↗
10-K for FY2021, filed Mar 18, 2022
−$29.9MView ↗
10-K for FY2021, filed Mar 18, 2022
−$33MView ↗
10-Q for Q1 FY2022, filed May 14, 2022
−$33.4MView ↗
8-K, filed Jun 3, 2022
On June 2, 2022, Zosano Pharma Corporation (the “Company”) received written notice from The Nasdaq Stock Market LLC (“Nasdaq”) indicating…View ↗
8-K, filed Jun 2, 2022
On June 1, 2022, the Company (the “Debtor”) filed a voluntary petition for relief under chapter 11 of title 11 (“Chapter 11”) of the United…View ↗
U.S. commercialization partner
The earlier report said Zosano intended to handle U.S. commercialization itself while considering collaborators; the latest report says it plans to rely on Eversana and other third parties.
10-K for FY2018, filed Mar 25, 2019 10-K for FY2021, filed Mar 17, 2022Develop and commercialize Qtrypta™ (M207). We believe that Qtrypta™ (M207), if approved by the FDA, will offer significant therapeutic and…View ↗
Competes with Teva Pharmaceutical Industries, GlaxoSmithKline, Eli Lilly &, AstraZeneca, Novartis, Allergan, Biohaven Pharmaceuticals, Lundbeck, Amgen, Merck &, Pfizer, Janssen Pharmaceutica, Endo International, Assertio, Upsher-Smith Laboratories, Satsuma Pharmaceuticals, Supernus Pharmaceutical, Currax Pharmaceuticals, Impel NeuroPharma, and Axsome Therapeutics
10-K for FY2021, filed Mar 17, 2022Companies marketing products or that have products in development to treat migraine or cluster headache which may compete with our M207 or…View ↗
Loading...
